{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Deyama S"],"funding":["Takeda Science Foundation","Japan Agency for Medical Research and Development","Uehara Memorial Foundation","Mochida Memorial Foundation for Medical and Pharmaceutical Research","YOKOYAMA Foundation for Clinical Pharmacology","Hokkoku Cancer Foundation","Japan Society for the Promotion of Science"],"pagination":["484-501"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10121976"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(2)"],"pubmed_abstract":["Intracerebroventricular infusion of resolvin E1 (RvE1), a bioactive metabolite derived from eicosapentaenoic acid, exerts antidepressant-like effects in a mouse model of lipopolysaccharide (LPS)-induced depression; these effects are blocked by systemic injection of rapamycin, a mechanistic target of rapamycin complex 1 (mTORC1) inhibitor. Additionally, local infusion of RvE1 into the medial prefrontal cortex (mPFC) or dorsal hippocampal dentate gyrus (DG) produces antidepressant-like effects. To evaluate the potential of RvE1 for clinical use, the present study examined whether treatment with RvE1 via intranasal (i.n.) route, a non-invasive route for effective drug delivery to the brain, produces antidepressant-like effects in LPS-challenged mice using tail suspension and forced swim tests"],"journal":["Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"],"pubmed_title":["Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex."],"pmcid":["PMC10121976"],"funding_grant_id":["YRY-1903","JP17K08360","21gm0910012h0004","JP19K07120","JP19H01014"],"pubmed_authors":["Kaneda K","Aoki S","Deyama S","Shuto S","Sugie R","Fukuda H","Minami M"],"additional_accession":[]},"is_claimable":false,"name":"Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex.","description":"Intracerebroventricular infusion of resolvin E1 (RvE1), a bioactive metabolite derived from eicosapentaenoic acid, exerts antidepressant-like effects in a mouse model of lipopolysaccharide (LPS)-induced depression; these effects are blocked by systemic injection of rapamycin, a mechanistic target of rapamycin complex 1 (mTORC1) inhibitor. Additionally, local infusion of RvE1 into the medial prefrontal cortex (mPFC) or dorsal hippocampal dentate gyrus (DG) produces antidepressant-like effects. To evaluate the potential of RvE1 for clinical use, the present study examined whether treatment with RvE1 via intranasal (i.n.) route, a non-invasive route for effective drug delivery to the brain, produces antidepressant-like effects in LPS-challenged mice using tail suspension and forced swim tests","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-06-02T19:25:40.176Z","creation":"2025-04-04T20:40:53.043Z"},"accession":"S-EPMC10121976","cross_references":{"pubmed":["36622634"],"doi":["10.1007/s13311-022-01337-1"]}}